Categories: News

Moderna to Host Third Annual Virtual Vaccines Day on March 24, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, MA / ACCESSWIRE / March 10, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its virtual Vaccines Day for analysts and investors at 8:00 a.m. ET on Thursday, March 24.

Moderna’s Vaccines Day will include presentations from management and key opinion leaders (KOLs) on Moderna’s mRNA vaccines and key considerations for vaccine development.

A live webcast will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for one year following the presentation.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View source version on accesswire.com:
https://www.accesswire.com/692272/Moderna-to-Host-Third-Annual-Virtual-Vaccines-Day-on-March-24-2022

Staff

Recent Posts

St. Baldrick’s Foundation Launches June Campaign to Honor Childhood Cancer Survivors and Support Lifesaving Research

Los Angeles, California--(Newsfile Corp. - June 3, 2025) - This National Cancer Survivor Month, St.…

4 hours ago

ThinkCyte Unveils MorphoScan Cloud: A Versatile Cloud-Based Platform for AI-Driven Cell Morphology Data Analysis

TOKYO, June 3, 2025 /PRNewswire/ -- ThinkCyte, a life science company pioneering advanced AI-powered cell…

4 hours ago

Healthie Launches Dev Assist: AI-Native Tooling for Rapid Healthcare App Development, Powered by the Model Context Protocol (MCP)

New open-source tool connects Healthie's GraphQL API to leading AI assistants via the Model Context…

4 hours ago

MATTERWORKS INC. SECURES SERIES A FUNDING TO ADVANCE MACHINE INTELLIGENCE FOR PREDICTIVE BIOLOGY

SOMERVILLE, Mass., June 3, 2025 /PRNewswire/ -- Matterworks, Inc., the category-defining pioneer unlocking unstructured molecular…

4 hours ago

Digital Pathology Market worth US$2.75 billion by 2030 with 13.5% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 3, 2025 /PRNewswire/ -- The global Digital Pathology Market, valued at US$1.29…

4 hours ago

Seven Corners Healthcare Invests in MobileOp4, Advancing Medical Access in Disasters and Rural Communities

CARMEL, Ind., June 3, 2025 /PRNewswire/ -- In further commitment to increasing health care access…

4 hours ago